NasdaqGS - Nasdaq Real Time Price USD

uniQure N.V. (QURE)

15.16

+0.45

+(3.06%)

As of 2:38:05 PM EDT. Market Open.

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. “We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Rachelle is a seas

GlobeNewswire yesterday

CRBP

AKTX

QURE
+3.06%
Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

The consensus price target hints at a 161.5% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 6 days ago

QURE
+3.06%
uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ...

Despite a significant drop in revenue, uniQure NV (QURE) strengthens its financial position and advances its clinical pipeline with promising developments in gene therapy.

GuruFocus.com 10 days ago

QURE
+3.06%
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of 23.36% and 73.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 11 days ago

QURE
+3.06%
UniQure: Q1 Earnings Snapshot

AMSTERDAM (AP) — UniQure NV (QURE) on Friday reported a loss of $43.6 million in its first quarter. On a per-share basis, the Amsterdam-based company said it had a loss of 82 cents. The results surpassed Wall Street expectations.

Associated Press Finance 11 days ago

QURE
+3.06%
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT-130; regulatory update expected in the second quarter of 2025 ~ ~ AMT-260 clinical data from first patient to be presented at Epilepsy Therapies & Diagnostics Development

GlobeNewswire 11 days ago

QURE
+3.06%
uniQure to Announce First Quarter 2025 Financial Results

~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial results before market open on Friday, May 9, 2025. Management will then host a conference call at 8:30 a.m. ET. As the Company advances its pipeline and AMT-130

GlobeNewswire 14 days ago

QURE
+3.06%
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?

CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 21 days ago

CGON

QURE
+3.06%
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 29 days ago

QURE
+3.06%

KNSA
FDA grants breakthrough status to uniQure’s Huntington’s disease therapy

Clinical data from the ongoing Phase I/II studies of the therapy support the designation.

Pharmaceutical Technology 29 days ago

QURE
+3.06%
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulatory update and guidance on the Biologics License Application submission expected in the second quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM, April 17, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S

GlobeNewswire last month

QURE
+3.06%
uniQure Full Year 2024 Earnings: Misses Expectations

uniQure ( NASDAQ:QURE ) Full Year 2024 Results Key Financial Results Revenue: US$27.1m (up 71% from FY 2023). Net loss...

Simply Wall St. 2 months ago

QURE
+3.06%
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of -240.91% and 85.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

QURE
+3.06%
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington’s disease; Initiated preparations for a potential Biologics License Application (BLA) submission ~ ~ Completed patient enrollment in the third cohort of the Phase I/II study of AMT-130 ~ ~ Initiated dosing of the Phase I/II study of AMT-260 in mesial temporal lobe epilepsy (mTLE); Implementing protocol changes to expand study inclusion criteria ~ ~

GlobeNewswire 2 months ago

QURE
+3.06%
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%

Key Insights Given the large stake in the stock by institutions, uniQure's stock price might be vulnerable to their...

Simply Wall St. 2 months ago

QURE
+3.06%
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

CSL Limited (OTC:CSLLY) and uniQure Inc (NASDAQ:QURE) announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dezaparvovec-drlb) for adults hemophilia B patients. The data showed that through four years, Hemgenix continues to deliver elevated and sustained factor IX activity levels, can offer long-term and greater bleed protection compared to prophylactic treatment, can eliminate the need for ro

Benzinga 3 months ago

QURE
+3.06%

CSL.AX
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec-drlb) for adults living with hemophilia B. In an oral presentation at the 18th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), data showed that through four years, HEMGENIX continues to deliver elevated and sustained factor I

PR Newswire 3 months ago

CMXHF

CSLLY

QURE
+3.06%
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~ ~ Company expects to initiate enrollment of second dose cohort in the first quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of enrollment in the first cohort of the Phase I/

GlobeNewswire 3 months ago

QURE
+3.06%
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~ ~ Company Expects to Initiate Enrollment of Second Dose Cohort in the First Quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM, Jan. 30, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Independent Data Monitoring Committee (IDM

GlobeNewswire 3 months ago

QURE
+3.06%
Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts?

We recently published a list of 12 Most Promising Growth Stocks According to Wall Street Analysts. In this article, we are going to take a look at where uniQure N.V. (NASDAQ:QURE) stands against other most promising growth stocks according to Wall Street analysts. Strategist Believes the Street is Underestimating the Tech Sector The new regulatory […]

Insider Monkey 3 months ago

QURE
+3.06%

Performance Overview

Return	QURE	S&P 500 (^GSPC)
YTD	-14.16%	+0.78%
1-Year	+212.58%	+11.67%
3-Year	+10.50%	+51.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

uniQure N.V. (QURE)

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ...

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

UniQure: Q1 Earnings Snapshot

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

uniQure to Announce First Quarter 2025 Financial Results

CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

FDA grants breakthrough status to uniQure’s Huntington’s disease therapy

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

uniQure Full Year 2024 Earnings: Misses Expectations

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts?

Performance Overview